Literature DB >> 21548470

Inflammatory breast cancer: what progress have we made?

Shaheenah Dawood1, Massimo Cristofanilli.   

Abstract

Inflammatory breast cancer (IBC) is a rare and aggressive subtype of locally advanced breast cancer (LABC). Its diagnosis is primarily clinical; however, a pathological confirmation of invasive cancer is required. Historically, IBC was a uniformly fatal disease. A major advance in the last three decades has been the introduction of a multidisciplinary approach to the management of this aggressive disease, incorporating pre-operative chemotherapy, surgery, and radiation therapy; this approach has significantly improved survival. Our review focuses on the progress made in the field of IBC research over the last decade, with particular attention to advances in the areas of epidemiology, molecular biology, arid clinical management.

Entities:  

Mesh:

Year:  2011        PMID: 21548470

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  18 in total

1.  MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer.

Authors:  Lei Huo; Yan Wang; Yun Gong; Savitri Krishnamurthy; Jing Wang; Lixia Diao; Chang-Gong Liu; Xiuping Liu; Feng Lin; William F Symmans; Wei Wei; Xinna Zhang; Li Sun; Ricardo H Alvarez; Naoto T Ueno; Tamer M Fouad; Kenichi Harano; Bisrat G Debeb; Yun Wu; James Reuben; Massimo Cristofanilli; Zhuang Zuo
Journal:  Mod Pathol       Date:  2016-02-26       Impact factor: 7.842

2.  Lymph node status in inflammatory breast cancer.

Authors:  Julie S Wecsler; Welela Tereffe; Rose C Pedersen; Michelle R Sieffert; Wendy J Mack; Haiyan Cui; Christy A Russell; Ryan R Woods; Rebecca K Viscusi; Stephen F Sener; Julie E Lang
Journal:  Breast Cancer Res Treat       Date:  2015-04-07       Impact factor: 4.872

3.  Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990-2008.

Authors:  Jennifer A Schlichting; Amr S Soliman; Catherine Schairer; David Schottenfeld; Sofia D Merajver
Journal:  Breast Cancer Res Treat       Date:  2012-06-26       Impact factor: 4.872

4.  Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer.

Authors:  Jennifer L Allensworth; Myron K Evans; François Bertucci; Amy J Aldrich; Richard A Festa; Pascal Finetti; Naoto T Ueno; Rachid Safi; Donald P McDonnell; Dennis J Thiele; Steven Van Laere; Gayathri R Devi
Journal:  Mol Oncol       Date:  2015-02-21       Impact factor: 6.603

5.  Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization.

Authors:  Kevin P Williams; Jennifer L Allensworth; Shalonda M Ingram; Ginger R Smith; Amy J Aldrich; Jonathan Z Sexton; Gayathri R Devi
Journal:  Cancer Lett       Date:  2013-05-17       Impact factor: 8.679

Review 6.  The rebel angel: mutant p53 as the driving oncogene in breast cancer.

Authors:  Dawid Walerych; Marco Napoli; Licio Collavin; Giannino Del Sal
Journal:  Carcinogenesis       Date:  2012-07-20       Impact factor: 4.944

7.  Inflammatory breast cancer: time to standardise diagnosis assessment and management, and for the joining of forces to facilitate effective research.

Authors:  D Rea; A Francis; A M Hanby; V Speirs; E Rakha; A Shaaban; S Chan; S Vinnicombe; I O Ellis; S G Martin; L J Jones; F Berditchevski
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

8.  EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells.

Authors:  Zhaomei Mu; Hua Li; Sandra V Fernandez; Katherine R Alpaugh; Rugang Zhang; Massimo Cristofanilli
Journal:  J Exp Clin Cancer Res       Date:  2013-09-27

9.  AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.

Authors:  Zhaomei Mu; Teresa Klinowska; Xiaoshen Dong; Emily Foster; Chris Womack; Sandra V Fernandez; Massimo Cristofanilli
Journal:  J Exp Clin Cancer Res       Date:  2014-05-30

10.  Topoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer.

Authors:  Tommaso Susini; Barbara Berti; Carlo Carriero; Ketty Tavella; Jacopo Nori; Ermanno Vanzi; Cecilia Molino; Mariarosaria Di Tommaso; Marco Santini; Valeria Saladino; Simonetta Bianchi
Journal:  Onco Targets Ther       Date:  2014-11-17       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.